At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 166 enrolled
Drug / intervention
Temozolomidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Trial Phase IIB Randomized, Multicenter, of Continuation or Non Continuation With 6 Cycles of Temozolomide After the First 6 Cycles of Standard First-line Treatment in Patients With Glioblastoma.
Grupo Español de Investigación en Neurooncología·interventional·Posted Aug 6, 2014·Updated Jan 12, 2021
In Brief
A Phase 2 clinical trial evaluating Temozolomide for Glioblastoma. Completed, enrolled 166 participants across 20 sites.
Detailed Summary
The purpose of this study is to show if prolonging treatment with temozolomide to 12 cycles improve progression-free survival in patients with glioblastoma included in this study, randomized according to o6-methylguanine-DNA-methyltransferase (MGMT) methylation status and residual disease or not, to receive an additional 6 cycles of temozolomide.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlioblastoma
CountriesSpain
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 2014
Enrollment StartAug 2014
Primary CompletionJun 2019
Study CompletionJun 2019
TodayJul 2026
First PostedAug 6, 2014
Enrollment StartAug 22, 2014
Primary CompletionJun 1, 2019
Study CompletionJun 14, 2019
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 11.9 years ago
Interventions
Temozolomidedrug